Search

Contagion Live article by Amer El-Ghali and Dana Holger reviewing phage-antibiotic combinations (PACs) in refractory multidrug-resistant infections: preclinical synergy is consistent and compassionate-use reports show safety and frequent cl

Cytophage formed a committee of independent and disinterested directors to evaluate strategic alternatives, including unsolicited strategic financing proposals. The board had not set a timetable or made a decision on a potential transaction

Final results of the randomized, placebo-controlled, double-blind Phase 1 trial of oral SNIPR001 in healthy volunteers were published in The Lancet Microbe. The trial evaluated safety and tolerability after twice-daily dosing for seven days

Lone Brøndsted and postdoc Rayen Quezada contribute phage-protein research to the END2AMR consortium at the University of Copenhagen. University of Copenhagen, Department of Veterinary and Animal Sciences

Unity Health Toronto profiles Gregory German and Steffanie Strathdee’s work on phage therapy. German has treated patients and led a Canadian-first trial for chronic infections; Strathdee helped assemble the cross-border team that treated he

Cytophage Announces Operational Restructuring. Cytophage News Releases

Gerdt Lab tackles antibiotic resistance using bacteriophages. www.gerdt.lab.indiana.edu

A team led by the Singapore-MIT Alliance for Research and Technology (SMART) AMR group, with MIT, the University of Otago and other partners, reports in Cell Host & Microbe a new type of phage DNA modification: arabinose added to cytosine a

Cytophage Announces Appointment of James Kinley as Chief Financial Officer. Cytophage News Releases

Marcin Borowicz received a NAWA Bekker award (2025 edition) of PLN 288,500 for a two-year project at the Australian Centre for Ecogenomics, University of Queensland, Brisbane. “Ecogenomics of tailocins: viral legacy in microbial interaction

Tristan Ferry, professor of infectious diseases and coordinator of the Reference Center for Complex Osteoarticular Infections (Crioac) at Hospices Civils de Lyon, explains how phage therapy works, its advantages (specificity, self-amplifica

Armata Pharmaceuticals announced on January 13, 2026 an FDA End-of-Phase 2 written response confirming that safety and efficacy data from its Phase 2a diSArm study support advancing AP-SA02, an intravenous S. aureus bacteriophage cocktail,

A $3.3 million NIAID contract supports a proof-of-concept clinical trial of LBP-PA01 for pneumonia, with further funding conditional on milestones. www.locus-bio.com

PHTRP lists a patient-perspective panel discussion on experiences with phage therapy. Phage Hunters Training and Research Program

PHTRP lists its fifth AMR and phage therapy panel discussion, “Building a Career in Phage Research.” Phage Hunters Training and Research Program

University of Otago researchers Prof Peter Fineran and Dr Robert Fagerlund are studying bacteriophages to tackle bacterial diseases in New Zealand cherry orchards, with funding from the Ministry of Business, Innovation and Employment (MBIE)

PhageLab CEO Hans Pieringer says the company created an algorithm that evaluates the genome of Salmonella bacteria to identify small differences and understand specific serotypes, antibiotic resistance and pathology, which helps create tail

Dr Piotr Golec of the Department of Molecular Virology, Institute of Microbiology, Faculty of Biology UW has received PLN 1,881,850 from the National Science Centre (NCN) under its OPUS 29 call for a project on interactions between lytic ph

UMC Utrecht has received a 4 million euro grant from the Promising Care scheme of the National Healthcare Institute and ZonMw for the first clinical study in the Netherlands of customized bacteriophage therapy for recurrent urinary tract in

Plaza Feed & Crop Nutrition has an exclusive agreement with Intralytix to use its bacteriophage products in phage kits for livestock production, pairing phages grouped to target E. coli, Salmonella and Listeria with Plaza's Cecabiotics prob